Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that local injection of anti-HSV sera in mice provided long-term protection against zoster-like skin lesions and sweating disturbances following an HSV-1 challenge.

This study observed that propranolol, flunarizine, and divalproex sodium were equally effective in managing migraine across a three-month period in a group of 84 patients, with various side effects noted among the drug groups.

In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.

This study concluded that Metformin may be suitable for prophylaxis or mild COVID-19, while a combination of Oseltamivir, Tamoxifen, and Dexamethasone could benefit moderate to severe cases, highlighting the need for more trials on other drug candidates.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

This study observed that patients who received Favipiravir treatment after having COVID-19 had lower positive pull test scores for telogen effluvium hair loss compared to those who did not, suggesting that Favipiravir may not influence the development of telogen effluvium.

This study reports that alopecia may develop in patients with chronic exposure to high plasma concentrations of valproate, but resolved after dose reduction or treatment discontinuation.

This study reported that COVID-19 patients treated with nirmatrelvir/ritonavir had lower anti-spike IgG levels and different cytokine patterns compared to those not receiving antiviral treatment, suggesting early antiviral use may alter immune response by reducing viral load and antigen presentation.

This study found that in lamivudine-resistant hepatitis B patients, tenofovir significantly reduced HBV DNA levels faster and more consistently than adefovir, reaching undetectable levels in all treated patients by 44 weeks.

This study observed that early treatment with azithromycin and either nitazoxanide, ivermectin, or hydroxychloroquine in COVID-19 patients may reduce viral shedding, symptom duration, and respiratory complications compared to untreated patients.

This study observed that while valproic acid treatment in children led to occasional mild clinical and laboratory side effects, no correlation with drug plasma levels was found.

This review discusses challenges in managing cutaneous drug reactions to anticonvulsants and reports no new clinical findings; the authors emphasize the complexity of discontinuing or rechallenging suspected agents.

This case report describes a rare association where herpes zoster infection may have triggered the first attack of NMOSD with systemic vasculitis in a patient, suggesting potential overlaps in immunopathogenesis.

This report highlights hyperpigmentation as an underreported side effect of topical cidofovir treatment for trichodysplasia spinulosa.

This study observed that valproic acid treatment led to a significant reduction in aggressive and impulsive behaviors among patients with acquired brain injury, with varying effects based on cognitive impairment degree; the treatment was generally well-tolerated, though some patients experienced temporary side effects.

This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.

This study found that in vivo, a novel microneedle system for valproic acid delivery may improve hair regrowth efficacy by upregulating hair follicle development pathways more effectively than topical application.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This review discusses the role of histone deacetylases in hearing loss, proposing potential pharmacological interventions, but reports no new clinical results.

This research found that combining a 308-nm excimer laser with oral compound glycyrrhizin and topical 0.03% tacrolimus was more effective for treating pediatric facial and cervical vitiligo, resulting in faster and higher rates of repigmentation with minimal adverse effects compared to glycyrrhizin and tacrolimus alone.

This article reviews valproate's impact on hair health, reporting both hair loss linked with oral use and early signs of hair regeneration from topical applications, without presenting new clinical results.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

In this study, the side effects of long-term sodium valproate treatment for refractory epilepsy were generally slight and transient, with severe side effects not observed.

In this study, researchers discovered that several compounds, including brequinar and 6-azauridine, exhibit significant anti-Zika virus activity using a high-throughput screen assay.

This study found that combining bromhexine and spironolactone was effective in improving clinical outcomes and reducing viral load or hospitalization duration in patients with mild to moderate COVID-19.

Applying valproic acid on the scalp increased hair growth in men with hair loss.

This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.

This review discusses the capabilities of ethosomes as drug delivery carriers and reports improved outcomes in a clinical study with an ethosomal acyclovir formulation.

In this study on short-term flutamide treatment in mice, no significant changes were observed in estrous cycle phases, but further research is needed to explore potential reproductive effects.